Cts-Clinical and Translational Science最新文献

{"title":"Radiomic-based biomarkers: Transforming age and body composition metrics into personalized age-informed indices","authors":"Radin Alikhani,&nbsp;Steven R. Horbal,&nbsp;Amy E. Rothberg,&nbsp;Manjunath P. Pai","doi":"10.1111/cts.70062","DOIUrl":"10.1111/cts.70062","url":null,"abstract":"<p>Chronological age has been the standard for quantifying the aging process. While it is simple to quantify it cannot fully discern the biological variability of aging between individuals. The growing body of interest in this variability of human aging has led to the introduction of new biomarkers to operationalize biological age. The inclusion of body composition may provide additional value to biological aging as a prediction and estimation factor of individual health outcomes. Diagnostic images based on radiomic techniques such as Computed Tomography contain an untapped wealth of patient-specific data that remain inaccessible to healthcare providers. These images are beneficial for collecting information from body composition that adds precision and granularity when compared to traditional measures. This information can subsequently be aggregated to construct models for changes in the human body associated with aging. In addition, aging leads to a natural decline in the best parameter of drug dosing in older adults, glomerular filtration rate. Since the conventional models of kidney function are correlated with age and body composition, the radiomic biomarkers representing age-related changes in body composition may also serve as potential new imaging biomarkers of kidney function for personalized dosing. Our review introduces potential radiomic biomarkers as measures of body composition change targeting the aging processes. As a functional example, we have hypothesized an age-related model of radiomics as a covariate of kidney function to improve personalized dosing. Future research focusing on evaluating this hypothesis in human subject studies is acknowledged.</p>","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"17 12","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11624483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Population pharmacokinetic analysis identifies an absorption process model for mycophenolic acid in patients with renal transplant","authors":"Yuki Suzuki,&nbsp;Noriko Matsunaga,&nbsp;Takahiko Aoyama,&nbsp;Chika Ogami,&nbsp;Chihiro Hasegawa,&nbsp;Satofumi Iida,&nbsp;Hideto To,&nbsp;Takashi Kitahara,&nbsp;Yasuhiro Tsuji","doi":"10.1111/cts.70097","DOIUrl":"https://doi.org/10.1111/cts.70097","url":null,"abstract":"<p>The pharmacokinetics (PKs) of mycophenolic acid (MPA) exhibit considerable complexity and large variability. We developed a population pharmacokinetic (popPK) model to predict the complex PK of MPA by examining an absorption model. Forty-two patients who had undergone renal transplantation were included in this study. popPK analysis, incorporating several absorption models, was performed using the nonlinear mixed-effects modeling program NONMEM. The MPA area under the concentration-time curve at 0–12 h (AUC0–12) was simulated using the final model to calculate the recommended dose. The PK of MPA was adequately described using a two-compartment model incorporating sequential zero- and first-order absorption with lag time. Total body weight, renal function (RF), and posttransplantation day (PTD) were included as covariates affecting MPA PK. The final model estimates were 7.56, 11.6 L/h, 104.0 L, 17.3 L/h, 169.0 L, 0.0453, 0.283, and 1.95 h for apparent nonrenal clearance, apparent renal clearance, apparent central volume of distribution, apparent intercompartmental clearance, apparent peripheral volume of distribution, absorption half-life, lag time, and duration of zero-order absorption, respectively. Simulation results showed that a dose regimen of 500–1000 mg twice daily is recommended during the early posttransplantation period. However, dose reduction could be required with increased PTD and decreased RF. The complex PK of MPA was explained using an absorption model. The developed popPK model can provide useful information regarding individual dosing regimens based on PTD and RF.</p>","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"17 12","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70097","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142764083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of carrot intake on glucose tolerance, microbiota, and gene expression in a type 2 diabetes mouse model","authors":"Morten Kobaek-Larsen,&nbsp;Sina Maschek,&nbsp;Stefanie Hansborg Kolstrup,&nbsp;Kurt Højlund,&nbsp;Dennis Sandris Nielsen,&nbsp;Axel Kornerup Hansen,&nbsp;Lars Porskjær Christensen","doi":"10.1111/cts.70090","DOIUrl":"https://doi.org/10.1111/cts.70090","url":null,"abstract":"<p>Type 2 diabetes (T2D) pathophysiology involves insulin resistance (IR) and inadequate insulin secretion. Current T2D management includes dietary adjustments and/or oral medications such as thiazolidinediones (TZDs). Carrots have shown to contain bioactive acetylenic oxylipins that are partial agonists of the peroxisome proliferator-activated receptor γ (<i>Pparg</i>) that mimic the antidiabetic effect of TZDs without any adverse effects. TZDs exert hypoglycemic effects through activation of <i>Pparg</i> and through the regulation of the gut microbiota (GM) producing short-chain fatty acids (SCFAs), which impact glucose and energy homeostasis, promote intestinal gluconeogenesis, and influence insulin signaling pathways. This study investigated the metabolic effects of carrot intake in a T2D mouse model, elucidating underlying mechanisms. Mice were fed a low-fat diet (LFD), high-fat diet (HFD), or adjusted HFD supplemented with 10% carrot powder for 16 weeks. Oral glucose tolerance tests were conducted at weeks 0 and 16. Fecal, cecum, and colon samples, as well as tissue samples, were collected at week 16 during the autopsy. Results showed improved oral glucose tolerance in the HFD carrot group compared to HFD alone after 16 weeks. GM analysis demonstrated increased diversity and compositional changes in the cecum of mice fed HFD with carrot relative to HFD. These findings suggest the potential effect of carrots in T2D management, possibly through modulation of GM. Gene expression analysis revealed no significant alterations in adipose or muscle tissue between diet groups. Further research into carrot-derived bioactive compounds and their mechanisms of action is warranted for developing effective dietary strategies against T2D.</p>","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"17 12","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70090","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142764224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of artery dissection during systemic exposure to vascular endothelial growth factor pathway inhibitors","authors":"Jun Okui,&nbsp;Takashi Waki,&nbsp;Kazuhiro Kajiyama,&nbsp;Sono Sawada,&nbsp;Shinya Watanabe,&nbsp;Yukari Namba,&nbsp;Ayano Kobayashi,&nbsp;Shuichi Kawarasaki,&nbsp;Kohei Amakasu,&nbsp;Toyotaka Iguchi,&nbsp;Naoya Horiuchi,&nbsp;Yoshiaki Uyama","doi":"10.1111/cts.70096","DOIUrl":"https://doi.org/10.1111/cts.70096","url":null,"abstract":"<p>Whether or not vascular endothelial growth factor pathway inhibitors (VPIs) increase the risk of artery dissection is still unknown. This study aimed to quantitatively evaluate the possibility of artery dissection as a class effect of VPIs using nationwide real-world data. This cohort study was conducted based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), which spans nearly the entire Japanese population of over 100 million individuals. We included the patients prescribed with 12 types of VPIs between 2012 and 2020. The incidence rate (IR) ratio of artery dissection for each VPI were estimated in comparison with bevacizumab, the only VPI in Japan with artery dissection listed in the package insert. Artery dissection as an outcome was targeted for acute artery dissection requiring hospitalization (including dissecting aneurysm). As a reference, a natural IR standardized by sex and age of bevacizumab-prescribed patients was also estimated using the direct method for the general population of NDB. Of 503,342 patients, the IR of artery dissection for bevacizumab was 44.4 (/100,000 person-years), and the adjusted IR ratios for each VPI compared with bevacizumab were consistently similar to or &gt;1.0. The IRs for each VPI were also higher than the crude natural IR (1.66/100,000 person-years; 95% CI: 1.59–1.73) and the standardized natural IR (2.18/100,000 person-years; 95% CI: 1.86–2.50). Real-world evidence suggests the risk of artery dissection as a class effect of VPIs. More attention on this risk will be necessary when using VPIs in clinical practice.</p>","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"17 12","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70096","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142762433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacogenetic-guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC-PGx): A multicenter clinical trial","authors":"Sarah Glewis,&nbsp;Senthil Lingaratnam,&nbsp;Benjamin Lee,&nbsp;Ian Campbell,&nbsp;Maarten IJzerman,&nbsp;Mussab Fagery,&nbsp;Sam Harris,&nbsp;Chloe Georgiou,&nbsp;Craig Underhill,&nbsp;Mark Warren,&nbsp;Robert Campbell,&nbsp;Madawa Jayawardana,&nbsp;S. Sandun M. Silva,&nbsp;Jennifer H. Martin,&nbsp;Jeanne Tie,&nbsp;Marliese Alexander,&nbsp;Michael Michael","doi":"10.1111/cts.70083","DOIUrl":"10.1111/cts.70083","url":null,"abstract":"<p>PACIFIC-PGx evaluated the feasibility of implementing pharmacogenetics (PGx) screening in Australia and the impact of <i>DPYD/UGT1A1</i> genotype-guided dosing on severe fluoropyrimidine (FP) and irinotecan-related toxicities and hospitalizations, compared to historical controls. This prospective single arm trial enrolled patients starting FP/irinotecan for any cancer between 7 January 2021 and 25 February 2022 from four Australian hospitals (one metropolitan, three regional). During the accrual period, 462/487 (95%) consecutive patients screened for eligibility for <i>DPYD</i> and 50/109 (46%) for <i>UGT1A1</i> were enrolled and genotyped (feasibility analysis), with 276/462 (60%) for <i>DPYD</i> and 30/50 (60%) for <i>UGT1A1</i> received FP/irinotecan (safety analysis). <i>DPYD</i> genotyping identified 96% (<i>n</i> = 443/462) Wild-Type, 4% (<i>n</i> = 19/462) Intermediate Metabolizers (50% dose reduction), and 0% Poor Metabolizers. <i>UGT1A1</i> genotyping identified 52% (<i>n</i> = 26/50) Wild-Type, 40% (<i>n</i> = 20/50) heterozygous, and 8% (<i>n</i> = 4/50) homozygous (30% dose reduction). Key demographics for the FP/irinotecan safety cohorts included: age range 23–89/34–74 years, male 56%/73%, Caucasian 83%/73%, lower gastrointestinal cancer 50%/57%. Genotype results were reported prior to cycle-1 (96%), average 5–7 days from sample collection. PGx-dosing for <i>DPYD</i> variant allele carriers reduced high-grade toxicities compared to historic controls (7% vs. 39%; OR = 0.11, 95% CI 0.01–0.97, <i>p</i> = 0.024). High-grade toxicities among Wild-Type were similar (14% vs. 14%; OR = 0.99, 95% CI 0.64–1.54, <i>p</i> = 0.490). PGx-dosing reduced FP-related hospitalizations (−22%) and deaths (−3.7%) compared to controls. There were no high-grade toxicities or hospitalizations for <i>UGT1A1*28</i> homozygotes. PGx screening and prescribing were feasible in routine oncology care and improved patient outcomes. Findings may inform expanded PGx programs within cancer and other disease settings.</p>","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"17 12","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70083","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Syndication in science: Curated collaboration","authors":"David B. Hurry,&nbsp;Elena S. Izmailova,&nbsp;Simon Davies,&nbsp;Olivier Harari,&nbsp;S. Aubrey Stoch,&nbsp;John A. Wagner","doi":"10.1111/cts.70085","DOIUrl":"10.1111/cts.70085","url":null,"abstract":"<p>Development and validation of digital measures require dedicated clinical studies, which can be conducted by a single study sponsor or a precompetitive collaboration. In this perspective, we propose an alternative model, data syndication, a curated collaboration, which foresees a technology provider being a founding member with biopharmaceutical sponsors and other stakeholders joining. Its main advantages are the speed of the study startup and the opportunity for real-time data streaming.</p>","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"17 12","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70085","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification","authors":"Jiajia Yuan,&nbsp;Lin Shen,&nbsp;Tian Shu Liu,&nbsp;HuiTing Xu,&nbsp;Jianwei Yang,&nbsp;Jia Wei,&nbsp;Haiping Jiang,&nbsp;Yanhong Deng,&nbsp;Hongming Pan,&nbsp;Yusheng Wang,&nbsp;Xiaotian Zhang,&nbsp;Zhi Peng,&nbsp;Changsong Qi,&nbsp;Lingli Zhang,&nbsp;Peiwen Hsu,&nbsp;Lin Song,&nbsp;Lei Mu,&nbsp;Qiao Sun,&nbsp;Jifang Gong,&nbsp;Cheng Lyu","doi":"10.1111/cts.70091","DOIUrl":"https://doi.org/10.1111/cts.70091","url":null,"abstract":"<p>Infigratinib, an <i>FGFR1-3</i> selective oral tyrosine kinase inhibitor, has shown clinical activity in cancers with <i>FGFR</i> alterations. The pharmacokinetics (PK) of infigratinib and its major metabolites have been characterized in global populations. This study examined the PK profile of infigratinib and its metabolites in Chinese patients. In this phase II, open-label, single-arm study in China, patients with advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) harboring <i>FGFR2</i> gene amplification received 125 mg infigratinib orally once daily in a “3 weeks on, 1 week off” schedule for 28-day cycles. Plasma PK parameters were calculated with a non-compartmental model. Data were available from 21 patients (19 GC and two GEJ). After a single dose, peak infigratinib plasma concentration was reached at a median time of 3.1 h, with geometric mean <i>C</i>_max of 85.9 ng/mL and AUC_0-<i>t</i> of 637 h*ng/mL. After 21-day dosing, geometric mean infigratinib <i>C</i>_max,ss of 204 ng/mL was reached at a median of 4.0 h; geometric mean AUC_0-24,ss was 3060 h*ng/mL. The geometric mean <i>R</i>_ac,_Cmax (%CV) and <i>R</i>_ac,_AUC0-24 (%CV) of infigratinib was 2.5 (113.8) and 5.1 (138.2), respectively. A steady state of infigratinib was reached after continuous dosing for 15 days. The metabolites accounting for &gt;10% of infigratinib were BHS697 and CQM157. The PK profiles of infigratinib and its metabolites in Chinese patients with GC or GEJ were largely consistent with known PK profiles of infigratinib from global populations.</p>","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"17 12","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70091","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of pharmacokinetics and tolerability following single-dose administration of molnupiravir in participants with hepatic or renal impairment","authors":"Kelly E. Duncan,&nbsp;Russ P. Carstens,&nbsp;Kristin L. Butterfield,&nbsp;Yoon Jin,&nbsp;Laura R. Inbody,&nbsp;Andrea K. Schaeffer,&nbsp;Catherine Z. Matthews,&nbsp;Tian Zhao,&nbsp;Shruti Patel,&nbsp;Brian M. Maas,&nbsp;Mickie H. Cheng,&nbsp;S. Aubrey Stoch","doi":"10.1111/cts.70073","DOIUrl":"10.1111/cts.70073","url":null,"abstract":"<p>Individuals with chronic liver or kidney disease are at increased risk of severe COVID-19. Molnupiravir is an orally administered antiviral authorized for the treatment of mild-to-moderate COVID-19 in adults at risk of progression to severe disease. Two nonrandomized, open-label, single-dose, multicenter, phase 1 trials were conducted to investigate the effects of hepatic and renal impairment on the tolerability and pharmacokinetics of molnupiravir (800 mg) and its metabolite β-D-N4-hydroxycytidine (NHC; NCT05386589/NCT05386758). The impact of renal impairment on urinary excretion of NHC was also assessed. The 90% CI for the geometric mean ratio of the plasma NHC area under the concentration–time curve (AUC) from zero to infinity was &lt;2.0 for participants with moderate hepatic or severe renal impairment versus healthy mean-matched controls. Comparable geometric mean values were observed for other pharmacokinetic parameters—including AUC from 0 to 12 h, AUC from zero to the last measurable concentration, and peak plasma concentration—in participants with moderate hepatic or severe renal impairment and in healthy mean-matched controls. Urinary excretion of NHC was low in healthy participants and participants with severe renal impairment; renal clearance was numerically lower in those with renal impairment. In both trials, all adverse events were of mild or moderate intensity and resolved by study completion. There were no clinically relevant treatment-related effects on other safety evaluations. Overall, molnupiravir was generally well-tolerated, with similar pharmacokinetic profiles in participants with hepatic or renal impairment and healthy participants, supporting its use for treating COVID-19 in these individuals without the need for dose adjustment.</p>","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"17 12","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70073","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142734375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deconvoluting zavegepant drug–drug interactions: A phase I study to evaluate the effects of rifampin and itraconazole on zavegepant pharmacokinetics","authors":"Rajinder Bhardwaj,&nbsp;Jo Ann Malatesta,&nbsp;Jennifer Madonia,&nbsp;Matt S. Anderson,&nbsp;Beth Morris,&nbsp;Kyle T. Matschke,&nbsp;Robert Croop,&nbsp;Richard Bertz,&nbsp;Jing Liu","doi":"10.1111/cts.70048","DOIUrl":"10.1111/cts.70048","url":null,"abstract":"<p>Zavegepant is a calcitonin gene-related peptide receptor antagonist for acute migraine treatment. This Phase I, open-label, fixed-sequence study evaluated the effects of itraconazole (a strong cytochrome P450 3A4 [CYP3A4] and P-glycoprotein [P-gp] inhibitor) on the pharmacokinetics of intranasal/oral zavegepant and the effects of rifampin (a strong inducer of CYP3A4 and P-gp; and an inhibitor of organic anion transporting polypeptide 1B3 [OATP1B3]) on oral zavegepant in healthy participants. In the intranasal/oral zavegepant–itraconazole cohort, participants received a single 10-mg dose of zavegepant nasal spray on Day 1, followed by oral zavegepant (50 mg) on Day 3. Itraconazole 200 mg once daily was administered from Days 4 to 12. On Day 7 zavegepant nasal spray and on Day 11 oral zavegepant were coadministered with itraconazole. In the oral zavegepant–rifampin cohort, participants received oral zavegepant (100 mg) on Day 1, rifampin 600 mg once daily on Days 2–10, and rifampin with zavegepant on Day 11. No significant change in zavegepant exposure was observed following coadministration of itraconazole with zavegepant nasal spray. For oral zavegepant coadministered with itraconazole, the area under the curve from 0 to infinity (AUC_0−inf) and the maximum observed concentration (<i>C</i>_max) of oral zavegepant increased by 59% and 77%, respectively. For oral zavegepant coadministered with rifampin, the AUC_0−inf and <i>C</i>_max of oral zavegepant increased by approximately 2.3- and 2.2-fold, respectively. These results suggest that OATP1B3 and intestinal P-gp are the more prominent pathways, as opposed to CYP3A4, for a zavegepant drug–drug interaction. Coadministration of OATP1B3 inhibitors with zavegepant nasal spray should be avoided.</p>","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"17 12","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70048","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia","authors":"Pavan Vaddady,&nbsp;Anaïs Glatard,&nbsp;Giovanni Smania,&nbsp;Shintaro Nakayama,&nbsp;Hiroyuki Inoue,&nbsp;Abhinav Kurumaddali,&nbsp;Malaz Abutarif,&nbsp;Ming Zheng","doi":"10.1111/cts.70074","DOIUrl":"10.1111/cts.70074","url":null,"abstract":"<p>The population pharmacokinetics (PK) of quizartinib and its pharmacologically active metabolite AC886 have been previously described in healthy volunteers (HV) and relapsed/refractory (R/R) FLT3-internal-tandem-duplication-positive (FLT3-IDT-positive) acute myeloid leukemia (AML) patients receiving quizartinib monotherapy. In this analysis, we characterized the population PK of quizartinib and AC886 in newly diagnosed FLT3-ITD-positive AML patients receiving standard induction and consolidation chemotherapy as background treatment, using data from the Phase 3 QuANTUM-First trial and 12 earlier studies. Quizartinib PK were best described by a three-compartment model with sequential zero- and first-order absorption and first-order elimination. A two-compartment model with first-order metabolite formation and first-order elimination best fitted AC886 data. The PK of both moieties showed large interindividual variability (approximately 70% coefficient of variation for systemic clearances). The use of strong cytochrome P450 3A (CYP3A) inhibitors had the largest impact on exposure, increasing the steady-state area under the curve during the dosing interval (AUC_ss) by 1.8-fold. This is consistent with observations in HV and R/R AML patients and confirms the need for dose adjustments during coadministration. A novel finding in newly diagnosed AML patients was the phase-dependent change in steady-state quizartinib exposure: dose-normalized AUC_ss values were 0.6-fold during induction, similar during consolidation, and 1.4-fold during continuation compared to R/R AML patients receiving quizartinib monotherapy. The present analysis highlighted the comparison of quizartinib and AC886 PK between newly diagnosed AML patients and previously studied populations, informed dose modifications needed with strong CYP3A inhibitors, and supported the use of derived individual exposure metrics in separate exposure-response analyses.</p>","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"17 12","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70074","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142733634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}